The National Challenge

The 5-year survival rate for women and men whose breast cancer is contained to the breast is 99%. Once breast cancer metastasizes to areas outside of the breast and surrounding regional lymph nodes, often to the bones, liver, lungs, or brain, the 5-year survival rate drops to 27%. It’s time to do better!

Susan G. Komen’s Bold Goal is to reduce breast cancer deaths by 50% in the U.S. by 2026. The key to achieving this goal is to increase the survival rates of people living with Metastatic Breast Cancer (MBC) by finding new treatments and cures through research. In fact, it is pretty simple. Research cures cancer. Nothing else does.

Learn more about Komen’s scope of research for MBC.

The Local Response

In the Triangle, we have a unique opportunity to motivate two world-class cancer research institutions to combine their research and compound their results. The Duke Cancer Institute and the UNC Lineberger Comprehensive Cancer Center are partnering with Komen in a first-of-its-kind collaborative effort focused on metastatic breast cancer research. This effort will be made possible through the
Susan G. Komen Metastatic Breast Cancer Collaborative Research Initiative.

Learn more about our local collaboration now.

The possibilities are endless and URGENT.

With an initial target to reach a $1 Million Dollar Milestone, the Komen MBC Collaborative Research Initiative will target and fund collaborative efforts between the Duke Cancer Institute and the UNC Lineberger Comprehensive Cancer Center, both already making progress independently toward understanding MBC. A gift to this fund will support unparalleled, lifesaving Triangle-based MBC research.

Meet the partners and supporters who make this work possible.

90% of all donations will directly fund research and 10% will fund administrative costs.

Download the Komen MBC Collaborative Research Initiative Case Statement.